Latest Headlines

Latest Headlines

Scripps scientists ID weakness-attacking antibodies in pursuit of HIV vaccine

A team at The Scripps Research Institute in La Jolla this week said they have identified four antibodies to target weaknesses in HIV, touting an "important advance" in HIV vaccine research that could assist in developing a vaccine.

Injectable HIV regimen being developed by J&J and ViiV Healthcare shows promise in trials

Johnson & Johnson's Janssen announced that a Phase IIb study of a combination regimen of two investigational long-acting injectable HIV drugs found that the therapy performed similarly to a regimen consisting of three oral medications.

Gilead snags FDA green light for 4-in-1 HIV combo

Gilead is facing mounting competition in the HIV space from players including GlaxoSmithKline's ViiV Healthcare. But now, it has a new combo product to tout in Genvoya, which won an FDA go-ahead Thursday. 

Gilead wins FDA approval for a new HIV combo pill with rivals at its heels

Gilead Sciences won FDA approval for another combination tablet designed to keep HIV from replicating itself, a drug the company touts as a safer alternative to products already on the market.

A-list academic consortium snaffles €23M to take HIV vaccine into clinic

A consortium of top-tier European research centers has snagged €23 million ($25 million) to take a HIV vaccine toward the clinic. The Imperial College London-led project is drawing on the scientific capabilities of 23 research centers in an attempt to move a HIV vaccine into Phase I within the next 5 years.

Roche launches rapid HIV, hep C tests in Europe

Roche is rolling out rapid tests for HIV, hepatitis C and hep C genotyping in Europe, continuing its molecular diagnostics winning streak a couple of weeks after scoring FDA approval for related tests and unveiling promising numbers for its testing business.

In snit over supply, not prices, MSF urges South Africa to override AbbVie drug patent

Doctors Without Borders (MSF) often has a bone to pick with Big Pharma, especially when it comes to the industry's patents on expensive life-extending meds. As part of its latest tirade, the group is urging the South African government to override a patent for AbbVie's HIV drug, Aluvia, after shortages of the med cropped up in the country.

HIV drug coupled with crystallized protease inhibitor boosts treatment

The efforts of two universities--one that developed the drug and one that developed the delivery system--have given way to a possible new HIV regimen that could cut treatments down to as few as one or two a year.

Industry and academia join sides to test DART therapy in HIV-infected cells

Scientists at Duke University Medical Center, the University of North Carolina, and the biotech MacroGenics have teamed up to design a molecule with the capacity to bind HIV-infected cells and unite them with the immune system's killer T cells.

Scripps Florida nets 4-year, $6M grant from Gates Foundation for HIV vaccine

In June, a team from The Scripps Research Institute in La Jolla, CA, met with federal regulators to discuss human trials for its investigational HIV vaccine. Now, researchers from the Scripps campus in Florida have won a four-year grant of up to $6 million from the Bill & Melinda Gates Foundation to develop a vaccine for HIV/AIDS that researchers there have been working on.